Novavax, Inc.
NASDAQ:NVAX
8.55 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Novavax, Inc. |
Symbool | NVAX |
Munteenheid | USD |
Prijs | 8.55 |
Beurswaarde | 1,369,581,750 |
Dividendpercentage | 0% |
52-weken bereik | 3.53 - 23.86 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. John Charles Jacobs M.B.A. |
Website | https://www.novavax.com |
An error occurred while fetching data.
Over Novavax, Inc.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)